• P-ISSN 0973-7200 E-ISSN 2454-8405
  • Follow us

Journal of Pharmaceutical Research

Article

Association of Mucormycosis in Covid-19 and its Epidemiologic Study
  • VIEWS 1987
  • PDF 408

Journal of Pharmaceutical Research

DOI: 10.18579/jopcr/v20i4.MS21073

Year: 2021, Volume: 20, Issue: 4, Pages: 88-96

Review Article

Association of Mucormycosis in Covid-19 and its Epidemiologic Study

Suchismita Mishra​ ✉ 1, Saurav Suman 1, Akshat Gupta 1, Neelima Mishra 1

1 Oriental College of Pharmacy, Oriental Campus, India

✉ Corresponding author: Suchismita Mishra; [email protected]

 

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Mucormycosis, also known as Zygomycosis or Black Fungus, is an infection caused in humans via various causative agents from the Zygomycetes class. Several countries including India is afflicted by the covid-19 virus, which has infected approximately 3.7 million people across the country. Some of the corona-positive patients suffer from another fatal infection, Mucormycosis, commonly known as Black Fungus. The strategy should be to administer an effective antifungal drug as soon as possible at the optimum dose. However, India being an epicenter of Diabetes with enormous 80 million diabetics, is of particular importance in the present scenario of the COVID pandemic. COVID therapy with Steroids and immune suppressants has increased the chances of infection in various individuals within the country with weaker immune system responses. The main purpose of this paper is to enlighten the community about the involvement of mucormycosis in covid-19 affected population and basic insights of its invasion.

 

Keywords

Mucormycosis, Black Fungus, Covid-19, Diabetes Mellitus, Amphotericin B, Immunosuppression, Apophysomyces, Renal Failure, Corticosteroids

References

  1. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in Human Disease. Clinical Microbiology Reviews. 2000;13(2):236–301. doi: 10.1128/cmr.13.2.236
  3. Jagdish C, Reetika S, Pallavi S, Jayanthi S, Divya P, Balasubramanya A. Mucormycosis of the paranasal sinus with gas forming maxillary osteomyelitis-a case report. The Internet Journal of Microbiology. 2012;10(1):1–6.
  4. Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. Journal of Fungi. 2019;5(1):26–44. doi: 10.3390/jof5010026
  6. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiology. 2013;8(9):1163–1175. doi: 10.2217/fmb.13.78
  7. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clinical Microbiology and Infection. 2009;15:2–9.
  8. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and Clinical Manifestations of Mucormycosis. Clinical Infectious Diseases. 2012;54(suppl_1):S23–S34. doi: 10.1093/cid/cir866
  9. Francis JR, Villanueva P, Bryant P, Blyth CC. Mucormycosis in Children: Review and Recommendations for Management. Journal of the Pediatric Infectious Diseases Society. 2018;7(2):159–164. doi: 10.1093/jpids/pix107
  11. Gass JDM. Ocular Manifestations of Acute Mucormycosis. Archives of Ophthalmology. 1961;65(2):226–237. doi: 10.1001/archopht.1961.01840020228012
  12. Harris JS, Mucormycosis. Mucormycosis: Report of a case. Pediatrics. 1955;16(6):857–867.
  15. Park JW, Chung JS, Lee S, Shin HJ. Neutropenic Enterocolitis due to Mucormycosis in a Patient with Myelodysplastic Syndrome. Infection & Chemotherapy. 2020;52(1):98. doi: 10.3947/ic.2020.52.1.98
  16. Shakir M, Maan MHA, Waheed S. Mucormycosis in a patient with COVID-19 with uncontrolled diabetes. BMJ Case Reports. 2021;14(7):e245343.
  17. Jalessi M, Bagheri SH, Azad Z, Firouzabadi FD, Amini E, Alizadeh R, et al. The outcome of olfactory impairment in patients with otherwise paucisymptomatic coronavirus disease 2019 during the pandemic. The Journal of Laryngology & Otology. 2021;135(5):426–435. doi: 10.1017/s0022215121001110
  18. Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in Organ and Stem Cell Transplant Recipients. Clinical Infectious Diseases. 2012;54:1–8. doi: 10.1093/cid/cis195
  19. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiology. 2013;8(9):1163–1175. doi: 10.2217/fmb.13.78
  20. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Singh B, et al. Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Current Research in Microbial Sciences. 2021;2:100057. doi: 10.1016/j.crmicr.2021.100057
  21. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in Human Disease. Clinical Microbiology Reviews. 2000;13(2):236–301. doi: 10.1128/cmr.13.2.236
  23. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. Journal of Fungi. 2020;6(4):265–284. doi: 10.3390/jof6040265
  24. Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. The Lancet Infectious Diseases. 2011;11:301–311. doi: 10.1016/s1473-3099(10)70316-9
  25. Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clinical Microbiology and Infection. 2009;15:60–65. doi: 10.1111/j.1469-0691.2009.02999.x
  26. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3) Haematologica. 2013;98(4):492–504. doi: 10.3324/haematol.2012.065110
  27. Almyroudis NG, Sutton DA, Fothergill AW, Rinaldi MG, Kusne S. In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. Antimicrobial Agents and Chemotherapy. 2007;51(7):2587–2590. doi: 10.1128/aac.00452-07
  28. Spellberg B, Walsh T, Kontoyiannis D, Jr., JE, Ibrahim A. Recent Advances in the Management of Mucormycosis: From Bench to Bedside. Clinical Infectious Diseases. 2009;48(12):1743–1751. doi: 10.1086/599105
  30. Diamond J. Diabetes in India. Nature. 2011;469(7331):478–479.
  32. Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9(3):523–534. doi: 10.3390/microorganisms9030523
  33. Dey D, Mukhopadhyay S, Mukherjee S. Black fungus in India during COVID-19: A systemic review. Int. J. Adv. Res. Biol. Sci. 2021;8(11):19–28.
  34. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia. 2021;186(2):289–298. doi: 10.1007/s11046-021-00528-2
  35. Narasimhaiah D, Poyuran R, Dharan B, Sandhyamani S. Mucormycosis-induced ileocecal perforation: A case report and review of literature. Journal of Postgraduate Medicine. 2020;66:48–50. doi: 10.4103/jpgm.jpgm_420_19
  36. Jaganathan V, Madesh VP, Subramanian S, Muthusamy RK, Mehta SS. Mucormycosis: an unusual masquerader of an endobronchial tumour. Respirology Case Reports. 2019;7(9):e00488. doi: 10.1002/rcr2.488

Copyright

© 2021 Published by Krupanidhi Educational Trust. This is an open-access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)

  • 18 February 2022

Year: 2021, Volume: 20, Issue: 4


More articles

DON'T MISS OUT!

Subscribe now for latest articles and news.